Susan Sobolov

Susan Sobolov is an accomplished executive in the pharmaceutical and biotechnology industries, currently serving as President at RIGImmune Inc. since May 2022. With a robust background in project and alliance management, Susan held the position of Chief Operating Officer at Caelum Biosciences from March 2019 to April 2022, and previously contributed as Vice President of Program Management at Fortress Biotech. As Executive Director at Alexion Pharmaceuticals, Susan led significant mRNA projects and global initiatives for enzyme replacement therapies. Additional experience includes leadership roles at Novartis, Vertex Pharmaceuticals, and Pfizer, spanning over two decades. Susan holds a PhD in Chemistry from Yale University and a BS in Chemistry from the University of Vermont.